Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. (30th June 2020)

• Record Type: Journal Article
• Authors: Ho, Hsi-en; Peluso, Michael J; Margus, Colton; Matias Lopes, Joao Pedro; He, Chen; Gaisa, Michael M; Osorio, Georgina; Aberg, Judith A; Mullen, Michael P
• Is Part Of: Journal of infectious diseases. Volume 223:Number 3(2021)
• Page Start: 403
• Page End: 408
• Publication Date: 2020-06-30
• Subjects: HIV -- people living with HIV -- COVID-19 -- SARS-CoV-2 -- coronavirus -- inflammation; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa380
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: We performed a retrospective study of coronavirus disease 2019 (COVID-19) in people with human immunodeficiency virus (PWH). PWH with COVID-19 demonstrated severe lymphopenia and decreased CD4 + T cell counts. Levels of inflammatory markers, including C-reactive protein, fibrinogen, D-dimer, interleukin 6, interleukin 8, and tumor necrosis factor α were commonly elevated. In all, 19 of 72 hospitalized individuals (26.4%) died and 53 (73.6%) recovered. PWH who died had higher levels of inflammatory markers and more severe lymphopenia than those who recovered. These findings suggest that PWH remain at risk for severe manifestations of COVID-19 despite antiretroviral therapy and that those with increased markers of inflammation and immune dysregulation are at risk for worse outcomes. Abstract : In this retrospective review of people with HIV and severe acute respiratory syndrome coronavirus 2 coinfection, COVID-19 was characterized by severe lymphopenia and elevated levels of inflammatory markers that were associated with adverse outcomes. Severe COVID-19 occurred despite suppressive antiretroviral therapy in this cohort.